Introduction: Breast cancer is known as the most common type of cancer in women, and this has raised the importance of its diagnosis in medical science as one of the most important issues. In addition to reducing costs, the diagnosis of benign or malignant breast cancer is very important in determining the treatment method.
Objective: The purpose of this paper is to present a model based on data mining techniques including feature selection and ensemble classification that can accurately predict breast cancer patients in the early stages.
Methodology: The proposed breast cancer detection model is developed by joining Adaptive Differential Evolution (ADE) algorithm for feature selection and Learning Vector Quantization (LVQ) neural network for classification. Our proposed model as ADE-LVQ has the ability to automatically and quickly diagnose breast cancer patients into two classes, benign and malignant. As a new evolutionary approach, ADE performs optimal configuration for LVQ neural network in addition to selecting effective features from breast cancer data. Meanwhile, we configure an ensemble classification technique based on LVQ, which significantly improves the prediction performance.
Results: ADE-LVQ has been analyzed from different perspectives on different datasets from Wisconsin breast cancer database. We apply different approaches to handle missing values and improve data quality on this database. The results of the simulations showed that the ADE-LVQ model is more successful than the equivalent and state-of-the-art models in diagnosing breast cancer patients. Also, ADE-LVQ provides better performance with less complexity, considering feature selection and ensemble learning. In particular, ADE-LVQ improves accuracy (up to 3.4%) and runtime (up to 2.3%) on average compared to the existing best method.
Conclusion: Combined methods based on data mining techniques for breast cancer diagnosis can help doctors in making better decisions for disease treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00432-023-05422-6 | DOI Listing |
PLoS One
January 2025
Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
This study presents T-1-NBAB, a new compound derived from the natural xanthine alkaloid theobromine, aimed at inhibiting VEGFR-2, a crucial protein in angiogenesis. T-1-NBAB's potential to interacts with and inhibit the VEGFR-2 was indicated using in silico techniques like molecular docking, MD simulations, MM-GBSA, PLIP, essential dynamics, and bi-dimensional projection experiments. DFT experiments was utilized also to study the structural and electrostatic properties of T-1-NBAB.
View Article and Find Full Text PDFBiochem J
January 2025
University of Dundee, Dundee, United Kingdom.
The maturation of the RNA cap involving guanosine N-7 methylation, catalyzed by the HsRNMT (RNA guanine-7 methyltransferase)-RAM (RNA guanine-N7 methyltransferase activating subunit) complex, is currently under investigation as a novel strategy to combat PIK3CA mutant breast cancer. However, the development of effective drugs is hindered by a limited understanding of the enzyme's mechanism and a lack of small molecule inhibitors. Following the elucidation of the HsRNMT-RAM molecular mechanism, we report the biophysical characterization of two small molecule hits.
View Article and Find Full Text PDFSoc Work Health Care
January 2025
German Cancer Society, Berlin, Germany.
Introduction: Outpatient cancer counseling centers (OCCs) are important social work facilities that provide support for cancer survivors who have psychosocial and sociolegal challenges. This paper explores clinical and sociodemographic characteristics, psychosocial burden as well as access routes of clients in OCCs seeking work-related counseling.
Methods: Between May 2022 and December 2023, data were collected in 19 OCCs, using questionnaires and documentation by counselors.
Annu Rev Med
January 2025
Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus and Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; email:
Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor-positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials-elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant-with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies.
View Article and Find Full Text PDFBiomol Biomed
January 2025
Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey.
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!